Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

CDER Outlines its Drug Safety Priorities During the Pandemic

  • Post author:Sam
  • Post published:March 1, 2021
  • Post category:Drug GMP Report

Like other parts of the FDA, the Center for Drug Evaluation and Research had to scramble last year to address COVID-19 while not losing sight of its other important tasks,…

Continue ReadingCDER Outlines its Drug Safety Priorities During the Pandemic

Alembic Pharmaceuticals Draws Form 483 Over Five Quality Observations

  • Post author:Sam
  • Post published:March 1, 2021
  • Post category:Drug GMP Report

Alembic Pharmaceuticals, a sterile drug manufacturer in Gujarat, India, drew a Form 483 inspection report from the FDA with five observations following a Jan. 28 – Feb. 6 inspection. Source:…

Continue ReadingAlembic Pharmaceuticals Draws Form 483 Over Five Quality Observations

Vaccine Developers Face Challenges in Scaling Up Manufacturing

  • Post author:Sam
  • Post published:March 1, 2021
  • Post category:Drug GMP Report

A Government Accountability Office (GAO) review of COVID-19 vaccine development efforts found that vaccine producers are facing significant manufacturing hurdles as they scale up operations. Source: Drug GMP Report

Continue ReadingVaccine Developers Face Challenges in Scaling Up Manufacturing

FDA Warns Florida Manufacturer Over Quality, Validation Concerns

  • Post author:Sam
  • Post published:March 1, 2021
  • Post category:Drug GMP Report

Allay Pharmaceuticals, a contract drug manufacturer in Hialeah, Florida, drew a warning letter from the FDA arising from a May 5-15, 2020 inspection in which investigators found serious quality lapses,…

Continue ReadingFDA Warns Florida Manufacturer Over Quality, Validation Concerns

AcelRx Pharmaceuticals Draws Warning Letter for Misleading Claims

  • Post author:Sam
  • Post published:March 1, 2021
  • Post category:Drug GMP Report

The FDA’s Office of Prescription Drug Promotion (OPDP) issued a warning letter to AcelRx Pharmaceuticals over false and misleading claims it made for its oral opioid Dsuvia (sufentanil). Source: Drug…

Continue ReadingAcelRx Pharmaceuticals Draws Warning Letter for Misleading Claims

Fresenius Kabi’s Cancer Drug Subsidiary Pleads Guilty to Destroying Records

  • Post author:Sam
  • Post published:March 1, 2021
  • Post category:Drug GMP Report

Fresenius Kabi Oncology (FKO) has agreed to plead guilty to hiding and destroying records prior to a 2013 FDA inspection and will hand over $50 million in fines and forfeiture,…

Continue ReadingFresenius Kabi’s Cancer Drug Subsidiary Pleads Guilty to Destroying Records

New Initial Question Coming Soon to FDA Adverse Event Reporting System

  • Post author:Sam
  • Post published:March 1, 2021
  • Post category:Drug GMP Report

In just over four months, drug manufacturers will experience a change in the FDA’s online adverse event report system to help the agency figure out what stage the product the…

Continue ReadingNew Initial Question Coming Soon to FDA Adverse Event Reporting System

EU Launches Vaccine Incubator to Take on Coronavirus Variants

  • Post author:Sam
  • Post published:February 17, 2021
  • Post category:Drug Industry Daily

The EU yesterday unveiled a plan to speed up regulatory approvals and manufacturing of vaccines against emerging strains of the SARS-CoV-2 virus that causes COVID-19. Source: Drug Industry Daily

Continue ReadingEU Launches Vaccine Incubator to Take on Coronavirus Variants

GSK and Vir Biotechnology Expand Monoclonal Antibody Partnership

  • Post author:Sam
  • Post published:February 17, 2021
  • Post category:Drug Industry Daily

GlaxoSmithKline (GSK) and Vir Biotechnology have teamed up to develop monoclonal antibodies for respiratory viruses, building off an existing agreement struck last year to develop COVID-19 therapies. Source: Drug Industry…

Continue ReadingGSK and Vir Biotechnology Expand Monoclonal Antibody Partnership

Report Shows 7.9 Percent of Drugs Ultimately Won Regulatory Approval Over Last Decade

  • Post author:Sam
  • Post published:February 17, 2021
  • Post category:Drug Industry Daily

The number of clinical trials that make it through to regulatory approval over the past decade is less than 8 percent, according to a new report on clinical success rates.…

Continue ReadingReport Shows 7.9 Percent of Drugs Ultimately Won Regulatory Approval Over Last Decade
  • Go to the previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.